Search

Bilberry

Dexpramipexole

Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to...

2-Hydroxylpropyl-beta-cyclodextrin

Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

Brensocatib

[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

Dexfenfluramine

Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. … For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.

Bezitramide

Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.

Pargyline

Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

Edonerpic

Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

Clazosentan

Clevudine